Table 1.
Characteristics and genotype frequencies of the study participants at entry
| Total (n = 57) | Control group (n = 19) | Efavirenz group (n = 19) | Nevirapine group (n = 19) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | ||||||||||||
| age (years) | 28 (25–34) | 27 (24–30) | 29 (23–35) | 32 (28–35) | ||||||||
| height (cm) | 160 (155–163) | 160 (154–165) | 157 (150–165) | 161 (155–164) | ||||||||
| weight (kg) | 57 (50–69) | 62 (49–78) | 56 (48–64) | 56 (51–82) | ||||||||
| CD4 count (cells/mm3) | 624 (441–1050) | 832 (624–1483) | 449 (274–1072) | 544 (428–853) | ||||||||
| Genotype frequencies | ||||||||||||
| CYP2B6 516G>T (rs3745274) (%) | GG | GT | TT | GG | GT | TT | GG | GT | TT | GG | GT | TT |
| 40 | 53 | 7 | 57 | 37 | 6 | 32 | 58 | 11 | 32 | 63 | 5 | |
| CYP2B6 983T>C (rs28399499) (%) | TT | CT | CC | TT | CT | CC | TT | CT | CC | TT | CT | CC |
| 82 | 18 | 0 | 84 | 16 | 0 | 84 | 16 | 0 | 79 | 21 | 0 | |
| CYP2B6 15582C>T (rs4803419) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 89 | 11 | 0 | 89 | 11 | 0 | 95 | 5 | 0 | 84 | 16 | 0 | |
| NR1I2 63396C>T (rs2472677) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 39 | 44 | 17 | 37 | 42 | 21 | 37 | 47 | 16 | 47 | 42 | 11 | |
| CYP3A4 392G>A (rs2740574) (%) | GG | AG | AA | GG | AG | AA | GG | AG | AA | GG | AG | AA |
| 47 | 44 | 9 | 47 | 37 | 16 | 42 | 58 | 0 | 53 | 37 | 10 | |
| ABCB1 4036A>G (rs3842) (%) | AA | AG | GG | AA | AG | GG | AA | AG | GG | AA | AG | GG |
| 70 | 14 | 16 | 84 | 11 | 5 | 58 | 21 | 21 | 68 | 11 | 21 | |
| ABCB1 3435C>T (rs1045642) (%) | CC | CT | TT | CC | CT | TT | CC | CT | TT | CC | CT | TT |
| 74 | 26 | 0 | 68 | 32 | 0 | 68 | 32 | 0 | 84 | 16 | 0 | |
Values are shown as median (IQR) and percentage of population.